Publicaciones en colaboración con investigadores/as de Hospital Universitario Marqués de Valdecilla (130)

2024

  1. Advanced fibrosis associated with non-alcoholic steatohepatitis (NASH) in Spain: results of a Delphi study

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 337-346

  2. Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?

    British Journal of Cancer, Vol. 130, Núm. 5, pp. 777-787

  3. Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis

    European Journal of Internal Medicine, Vol. 129, pp. 78-86

  4. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature

    Arthritis Research and Therapy, Vol. 26, Núm. 1

  5. Levodopa-Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5-Year Follow-Up Study

    Movement Disorders Clinical Practice, Vol. 11, Núm. 7, pp. 830-849

  6. LiverAI: New tool in the landscape for liver health

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 6, pp. 646-648

  7. Measurement Assessment of Minimal Disease Activity In Psoriasis in Spain: A National Cross-Sectional Study

    Actas Dermo-Sifiliograficas

  8. Outcomes and factors associated with relapse of vaccine-induced liver injury after SARS CoV-2 immunization: A nationwide study

    Annals of Hepatology, Vol. 29, Núm. 3

  9. Predictive factors for decompensating events in patients with cirrhosis with primary biliary cholangitis under different lines of therapy

    Hepatology (Baltimore, Md.), Vol. 80, Núm. 4, pp. 791-806

  10. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 2, pp. 201-211

  11. Recommendations for the diagnosis and treatment of anti-neutrophil cytoplasmic autoantibody associated vasculitis

    Nefrologia

  12. Rituximab is a safe and effective alternative treatment for patients with autoimmune hepatitis: Results from the ColHai registry

    Liver International, Vol. 44, Núm. 9, pp. 2303-2314

  13. Surgery for inflammatory bowel disease in Spain: How are we doing? Initial results of a nationwide prospective registry

    Cirugia Espanola, Vol. 102, Núm. 7, pp. 355-363

  14. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597

2023

  1. Adult T-cell leukemia/lymphoma in HTLV-1 non-endemic regions

    Journal of Clinical Virology, Vol. 167

  2. Alemtuzumab treatment in real clinical practice: Experience in a multicenter cohort.

    Multiple Sclerosis and Related Disorders, Vol. 75

  3. Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP

    Journal of Clinical Medicine, Vol. 12, Núm. 14

  4. Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration

    Hepatology, Vol. 77, Núm. 4, pp. 1095-1105

  5. Changes in Principal Caregiver Mood Affects the Mood of the Parkinson's Disease Patient: The Vicious Cycle of Illness

    Journal of Parkinson's disease, Vol. 13, Núm. 2, pp. 219-231

  6. Clinical utility of a personalized and long-term monitoring device for Parkinson's disease in a real clinical practice setting: An expert opinion survey on STAT-ON™

    Neurologia, Vol. 38, Núm. 5, pp. 326-333